Citius pharmaceuticals, inc. (CTXR)
CashFlow / Yearly
Sep'19Sep'18Sep'17Sep'16Sep'15Sep'14Dec'13Sep'13Sep'12Sep'11
Cash Flows From Operating Activities:
Net Loss

-15,562

-12,536

-10,384

-8,295

-2,902

-737

-1,288

-31

-22

-26

Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of debt issuance costs

-

-

-

-

-

-

28

-

-

-

Stock-based compensation - general and administrative

715

779

986

732

486

470

0

-

-

-

Loss (gain) on revaluation of derivative warrant liability

-

-

-

-

-

8

-

-

-

-

Amortization of debt issuance costs

-

-

-

-

-

14

-

-

-

-

Gain on revaluation of derivative warrant liability

-

-

452

-

-

-

0

-

-

-

(Gain) loss on revaluation of derivative warrant liability

-

-

-

-838

332

-

-

-

-

-

Gain on extinguishment of liability

-

450

-

0

-

-

-

-

-

-

Issuance of common stock for services and release agreements

211

-

704

-

-

-

-

-

-

-

Issuance of common stock for services and release agreements

-

377

-

150

0

-

-

-

-

-

Fair value of options issued to purchase units of common stock

-

0

104

0

0

-

-

-

-

-

Warrants issued and repriced in settlement agreements

-

0

190

0

0

-

-

-

-

-

Non-cash interest expense

-

0

762

0

0

-

-

-

-

-

Stock issued for services

-

-

-

-

-

0

-

-

-

-

Depreciation

0

1

2

1

0

0

-

-

-

-

Write-off of abandoned trademarks

-

0

-

5

0

-

-

-

-

-

Write-off of abandoned trademarks

-

-

-

-

-

0

-

-

-

-

Changes in operating assets and liabilities:
Other receivables

-818

818

-

0

-

-

-

-

-

-

Prepaid expenses

-9

-162

-572

40

60

9

-9

-

-

-

Deposits

-54

-

-

-

-

-

-

-

-

-

Accounts payable

1,140

971

-306

105

452

-66

75

11

-0

0

Accrued expenses

64

70

-397

351

-52

56

3

-1

0

3

Accrued compensation

201

135

159

288

0

-

-

-

-

-

Accrued compensation

-

-

-

-

-

0

-

-

-

-

Accrued interest - related parties

-16

-15

-87

-7

-7

79

77

-

-

-

Due to related party

-

-27

-

-42

14

0

18

-

-

-

Accrued interest, related party

-

-

-

-

-

-

-

0

1

0

Accrued interest

-

-

-

-

-

-

-

0

0

0

Net Cash Used In Operating Activities

-12,437

-11,318

-7,971

-5,900

-2,385

-183

-1,095

-20

-20

-20

Cash acquired in acquisition

-

0

-

255

0

0

-

-

-

-

Purchase of property and equipment

-

0

2

0

0

-

-

-

-

-

Net Cash Provided By (Used In) Investing Activities

-

0

-2

255

0

0

-

0

0

0

Proceeds from (repayments of) bank overdrafts

-

-

-

-

-

-

-

0

0

-

Proceeds from notes payable – related parties

-

0

4,210

500

0

-

-

34

3

27

Repayment of notes payable - related parties

-

0

-

-600

0

-

-

-

-

-

Net proceeds from common stock warrant exercises

23

1,125

-

0

-

-

-

-

-

-

Proceeds from stock option exercise

-

0

0

0

0

-

-

-

-

-

Net proceeds from underwritten offerings

6,290

-

-

-

-

-

-

-

-

-

Net proceeds from common stock and warrants in August 2018 offering

-

8,926

-

0

-

-

-

-

-

-

Net proceeds from registered direct offering

-4,834

-7,246

-

0

-

-

-

-

-

-

Proceeds from notes payable - related parties

-

-

-

-

-

0

-

-

-

-

Repayment of notes payable

-

-

-

-

-

0

-

-

-

-

Proceeds from convertible promissory notes

-

-

-

-

-

-

225

-

-

-

Proceeds from promissory notes

-

-

-

-

-

-

600

-

-

-

Proceeds from subordinated convertible promissory note

-

-

-

-

-

-

350

-

-

-

Repayments of related party debt

-

-

-

-

-

-

-

0

0

8

Repayments of debt

-

-

-

-

-

-

-

30

0

-

Proceeds from issuance of common stock

-

-

-

-

-

50

0

0

0

0

Net proceeds from private placement

-

0

556

5,427

1,509

1,630

0

-

-

-

Net proceeds from public offering

-

-

6,116

-

0

-

-

-

-

-

Deferred offering costs

-

0

-

64

0

-

-

-

-

-

Deferred offering costs

-

-

-

-

-

0

-

-

-

-

Deferred offering costs

-

-

-

-

-

-

25

-

-

-

Debt issuance costs

-

-

-

-

-

-

-42

-

-

-

Proceeds from non-related party debt

-

-

-

-

-

-

-

16

17

0

Net Cash Provided By Financing Activities

11,147

17,298

10,883

5,262

1,509

1,680

1,108

20

20

18

Net Change in Cash and Cash Equivalents

-1,290

5,979

2,909

-381

-875

1,497

12

-0

-0

-2

Supplemental Disclosures Of Cash Flow Information and Non-cash Activities:
Interest paid

-

0

1

1

0

-

-

-

-

-

Premium on convertible promissory notes – related party

-

0

833

0

0

-

-

-

-

-

Fair value of unit purchase option issued for future services

-

0

193

477

0

-

-

-

-

-

Fair value of unit purchase option issued for future services

-

0

-

0

0

-

-

-

-

-

Interest paid

-

-

-

-

-

0

0

0

0

0

Income taxes paid

-

-

-

-

-

0

0

0

0

0

Fair value of warrants recorded as derivative warrant liability

-

-

641

-

768

1,459

-

-

-

-

Fair value of warrants issued for services

-

-

-

-

-

0

-

-

-

-

Reclassification of derivative warrant liability to additional paid-in capital

-

0

1,229

1,093

1,148

0

0

-

-

-

Beneficial conversion feature on convertible promissory notes – related party

-

-

1,595

-

0

-

-

-

-

-

Conversion of convertible promissory notes – related party and related accrued interest into common stock

-

0

4,786

0

633

-

-

-

-

-

Par value of common stock issued upon cashless exercise of warrants

-

0

-

0

-

-

-

-

-

-

Fair value of private placement warrants recorded as derivative warrant liability

-

-

-

-

-

-

0

-

-

-

Conversion of promissory notes and accrued interest into common stock

-

-

-

-

-

0

0

-

-

-

Conversion of convertible promissory notes and accrued interest into common stock

-

-

-

-

-

1,836

0

-

-

-

Conversion of subordinated convertible promissory note and accrued interest into common stock

-

-

-

-

-

394

0

-

-

-